The combination of SGLT2i and RASi therapies may lead to a synergistic effect of vasoconstriction of the afferent arteriole and vasodilation of the efferent arteriole, which reduces the intraglomerular pressure in patients with diabetic kidney diseases (25, 26). The gene discussed is MMP19; the disease is diabetic kidney disease.